NEW Research—First human trial of #COVID19 vaccine finds it is safe and induces rapid immune response: finding from a dose-escalation, single-centre, open-label, non-randomised, phase 1 trial https://hubs.ly/H0qMrl-0 

Thread (1/3)

Vaccine candidate was well tolerated at all doses with no serious adverse events reported within 28 days. Most adverse events were mild or moderate; 83% of those receiving low & middle doses & 75% in the high dose group reporting at least 1 adverse reaction within 7 days (2/3)

Study of 108 adults finds vaccine produced neutralising antibodies and T-cell response against SARS-CoV-2, but further research is needed to confirm whether the vaccine protects against #SARSCoV2 infection (3/3)